Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Argent Capital Management LLC

Argent Capital Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,662 shares of the medical research company's stock after selling 2,049 shares during the period. Argent Capital Management LLC's holdings in Thermo Fisher Scientific were worth $19,073,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. IFG Advisors LLC increased its position in Thermo Fisher Scientific by 3.3% during the 3rd quarter. IFG Advisors LLC now owns 532 shares of the medical research company's stock valued at $329,000 after buying an additional 17 shares in the last quarter. Trivant Custom Portfolio Group LLC grew its holdings in shares of Thermo Fisher Scientific by 0.4% during the third quarter. Trivant Custom Portfolio Group LLC now owns 4,398 shares of the medical research company's stock valued at $2,720,000 after buying an additional 19 shares during the last quarter. Axiom Advisory LLC raised its holdings in Thermo Fisher Scientific by 1.6% in the 3rd quarter. Axiom Advisory LLC now owns 1,216 shares of the medical research company's stock worth $720,000 after acquiring an additional 19 shares during the last quarter. Angeles Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. Angeles Wealth Management LLC now owns 3,921 shares of the medical research company's stock worth $2,425,000 after purchasing an additional 19 shares in the last quarter. Finally, Bangor Savings Bank lifted its holdings in shares of Thermo Fisher Scientific by 6.0% during the fourth quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock valued at $174,000 after purchasing an additional 19 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 1.8 %

NYSE TMO traded up $10.04 on Thursday, hitting $561.51. 1,831,147 shares of the stock were exchanged, compared to its average volume of 2,147,115. The stock has a fifty day moving average price of $529.69 and a two-hundred day moving average price of $568.01. The firm has a market capitalization of $214.78 billion, a P/E ratio of 35.20, a P/E/G ratio of 3.59 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the prior year, the business posted $5.69 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.78%.

Thermo Fisher Scientific declared that its board has approved a stock buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company's management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on TMO shares. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research note on Thursday, October 24th. Scotiabank started coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a "sector perform" rating and a $605.00 price target on the stock. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Royal Bank of Canada dropped their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $648.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares of the company's stock, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the business's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares of the company's stock, valued at $7,134,197.76. This trade represents a 13.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock valued at $25,954,465 in the last ninety days. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.